Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 19.4% on Thursday . The company traded as low as C$0.14 and last traded at C$0.15. 519,694 shares were traded during mid-day trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Price Performance
The stock’s fifty day moving average price is C$0.20 and its two-hundred day moving average price is C$0.12. The firm has a market capitalization of C$25.50 million, a price-to-earnings ratio of -5.10 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What is the S&P 500 and How It is Distinct from Other Indexes
- Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
- There Are Different Types of Stock To Invest In
- MarketBeat Week in Review – 02/17 – 02/21
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- SolarEdge: A Surprising Bright Spot in a Troubled Solar Industry?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
